Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Index Rebalance

The Korea Exchange (KRX) will announce the results of the June 2021 review of the <a href="https://www.smartkarma.com/entities/kosdaq-150-index" target="_blank" data-smartkarma-citation="entities:31077:1" rel="noopener">KOSDAQ 150 Index (KOSDQ150 INDEX)</a>  in May with the changes becoming effective after the close of trading on 10 June.We see 14 potential changes to the index in the June review and we are less than a third of the way through the review period. The end of the short sell ban in March could bring a lot more changes to the index.The potential inclusions are <a href="https://www.smartkarma.com/entities/tesna-inc" target="_blank" data-smartkarma-citation="entities:8792:1" rel="noopener">Tesna Inc (131970 KS)</a>, <a href="https://www.smartkarma.com/entities/unison-co-ltd-south-korea" target="_blank" data-smartkarma-citation="entities:18617:1" rel="noopener">Unison Co Ltd (018000 KS)</a>, <a href="https://www.smartkarma.com/entities/tse-co-ltd" target="_blank" data-smartkarma-citation="entities:17821:1" rel="noopener">Tse Co Ltd (131290 KS)</a>, ABPro Bio (195990 KS), <a href="https://www.smartkarma.com/entities/icure-pharm-inc" target="_blank" data-smartkarma-citation="entities:27142:1" rel="noopener">Icure Pharm Inc (175250 KS)</a>, <a href="https://www.smartkarma.com/entities/sam-kang-m-t-co-ltd" target="_blank" data-smartkarma-citation="entities:7263:1" rel="noopener">Sam Kang M&amp;T (100090 KS)</a>, <a href="https://www.smartkarma.com/entities/simmtech-co-ltd" target="_blank" data-smartkarma-citation="entities:28871:1" rel="noopener">SIMMTECH Co Ltd (222800 KS)</a>, <a href="https://www.smartkarma.com/entities/binex-co-ltd" target="_blank" data-smartkarma-citation="entities:1949:1" rel="noopener">Binex Co Ltd (053030 KS)</a>, Vaxcell Bio (323990 KS), <a href="https://www.smartkarma.com/entities/kmh-co-ltd" target="_blank" data-smartkarma-citation="entities:18525:1" rel="noopener">Kmh Co Ltd (122450 KS)</a>, <a href="https://www.smartkarma.com/entities/solid-inc" target="_blank" data-smartkarma-citation="entities:14701:1" rel="noopener">Solid Inc (050890 KS)</a>, PSK Inc (319660 KS), AJu IB Investment (027360 KS) and <a href="https://www.smartkarma.com/entities/kpm-tech-co-ltd" target="_blank" data-smartkarma-citation="entities:15948:1" rel="noopener">Kpm Tech Co Ltd (042040 KS)</a>. The potential exclusions are <a href="https://www.smartkarma.com/entities/stcube" target="_blank" data-smartkarma-citation="entities:4872:1" rel="noopener">Stcube (052020 KS)</a>, <a href="https://www.smartkarma.com/entities/daea-ti-co-ltd" target="_blank" data-smartkarma-citation="entities:1473:1" rel="noopener">Daea Ti Co Ltd (045390 KS)</a>, <a href="https://www.smartkarma.com/entities/spigen-korea-co-ltd" target="_blank" data-smartkarma-citation="entities:9852:1" rel="noopener">Spigen Korea (192440 KS)</a>, <a href="https://www.smartkarma.com/entities/jusung-engineering-co-ltd" target="_blank" data-smartkarma-citation="entities:12277:1" rel="noopener">Jusung Engineering (036930 KS)</a>, <a href="https://www.smartkarma.com/entities/advanced-process-systems-corporation" target="_blank" data-smartkarma-citation="entities:24087:1" rel="noopener">Advanced Process Systems (265520 KS)</a>, <a href="https://www.smartkarma.com/entities/saraminhr-co-ltd" target="_blank" data-smartkarma-citation="entities:8494:1" rel="noopener">Saraminhr (143240 KS)</a>, <a href="https://www.smartkarma.com/entities/vt-gmp-co-ltd" target="_blank" data-smartkarma-citation="entities:8056:1" rel="noopener">Gmp Co Ltd (018290 KS)</a>, <a href="https://www.smartkarma.com/entities/iriver-ltd" target="_blank" data-smartkarma-citation="entities:13005:1" rel="noopener">Iriver Ltd (060570 KS)</a>, <a href="https://www.smartkarma.com/entities/innox-advanced-materials-co-ltd" target="_blank" data-smartkarma-citation="entities:24223:1" rel="noopener">Innox Advanced Materials Co,Ltd. (272290 KS)</a>, <a href="https://www.smartkarma.com/entities/ebest-investment-securitie" target="_blank" data-smartkarma-citation="entities:18895:1" rel="noopener">Ebest Investment &amp; Securitie (078020 KS)</a>, <a href="https://www.smartkarma.com/entities/sangsangin-co-ltd" target="_blank" data-smartkarma-citation="entities:10494:1" rel="noopener">Sangsangin Co., Ltd. (038540 KS)</a>, <a href="https://www.smartkarma.com/entities/shinheung-sec" target="_blank" data-smartkarma-citation="entities:24426:1" rel="noopener">Shin Heung Energy &amp; Electronics Co (243840 KS)</a>, <a href="https://www.smartkarma.com/entities/neopharm-co-ltd" target="_blank" data-smartkarma-citation="entities:10273:1" rel="noopener">Neopharm Co Ltd (092730 KS)</a> and <a href="https://www.smartkarma.com/entities/hlscience-co-ltd" target="_blank" data-smartkarma-citation="entities:23629:1" rel="noopener">HLSCIENCE Co. (239610 KS)</a>.One-way turnover is estimated at 5.44%. While the impact of passive funds is not high on the expected inclusions, the impact on the expected exclusions is much higher.

The Korea Exchange (KRX) will announce the results of the June 2021 review of the KOSDAQ 150 Index (KOSDQ150 INDEX)  in May with the changes becoming effective after the close of trading on 10 June.We see 14 potential changes to the index in the June review and we are less than a third of the way through the review period. The end of the short sell ban in March could bring a lot more changes to the index.The potential inclusions are Tesna Inc (131970 KS), Unison Co Ltd (018000 KS), Tse Co Ltd (131290 KS), ABPro Bio (195990 KS), Icure Pharm Inc (175250 KS), Sam Kang M&amp;T (100090 KS), SIMMTECH Co Ltd (222800 KS), Binex Co Ltd (053030 KS), Vaxcell Bio (323990 KS), Kmh Co Ltd (122450 KS), Solid Inc (050890 KS), PSK Inc (319660 KS), AJu IB Investment (027360 KS) and Kpm Tech Co Ltd (042040 KS). The potential exclusions are Stcube (052020 KS), Daea Ti Co Ltd (045390 KS), Spigen Korea (192440 KS), Jusung Engineering (036930 KS), Advanced Process Systems (265520 KS), Saraminhr (143240 KS), Gmp Co Ltd (018290 KS), Iriver Ltd (060570 KS), Innox Advanced Materials Co,Ltd. (272290 KS), Ebest Investment &amp; Securitie (078020 KS), Sangsangin Co., Ltd. (038540 KS), Shin Heung Energy &amp; Electronics Co (243840 KS), Neopharm Co Ltd (092730 KS) and HLSCIENCE Co. (239610 KS).One-way turnover is estimated at 5.44%. While the impact of passive funds is not high on the expected inclusions, the impact on the expected exclusions is much higher.

KOSDAQ150 Index Rebalance Preview: Lots of Changes Expected Already; More to Come

The KRX announced the list of inclusions and exclusions to the KOSDAQ150 Index today. The rebalance is effective as of 12 June and all passive buying/selling will be done at the closing auction on 11 June.There are 14 inclusions and 14 exclusions in the June 2020 review with an expected one-way turnover of 5.15%.The inclusions and exclusions are shown in the table below<table class="table table-striped">
<colgroup>
<col>
<col>
<col>
<col>
</colgroup>
<tbody>
<tr>
<td style="text-align: center; width: 230pt;" colspan="2">INCLUSIONS</td>
<td style="text-align: center; width: 219pt;" colspan="2">EXCLUSIONS</td>
</tr>
<tr>
<td>018290.KQ</td>
<td>VT GMP Co Ltd</td>
<td>007820.KQ</td>
<td>SM Core Inc</td>
</tr>
<tr>
<td>032190.KQ</td>
<td>Daou Data Corp</td>
<td>013030.KQ</td>
<td>HY-Lok Corp</td>
</tr>
<tr>
<td>038540.KQ</td>
<td>Sangsangin Co Ltd</td>
<td>016250.KQ</td>
<td>eTEC E&amp;C Ltd</td>
</tr>
<tr>
<td>041190.KQ</td>
<td>Woori Technology Investment Co Ltd</td>
<td>019210.KQ</td>
<td>YG-1 Co Ltd</td>
</tr>
<tr>
<td>052260.KQ</td>
<td>SK Bio Land Co Ltd</td>
<td>036630.KQ</td>
<td>Sejong Telecom Inc</td>
</tr>
<tr>
<td>060720.KQ</td>
<td>KH Vatec Co Ltd</td>
<td>041140.KQ</td>
<td>Nexon GT Co Ltd</td>
</tr>
<tr>
<td>078020.KQ</td>
<td>eBEST Investment &amp; Securities Co Ltd</td>
<td>044490.KQ</td>
<td>Taewoong Co Ltd</td>
</tr>
<tr>
<td>078070.KQ</td>
<td>Ubiquoss Holdings Inc</td>
<td>045100.KQ</td>
<td>Hanyang ENG Co Ltd</td>
</tr>
<tr>
<td>084370.KQ</td>
<td>Eugene Technology Co Ltd</td>
<td>067390.KQ</td>
<td>AeroSpace Technology of Korea Inc</td>
</tr>
<tr>
<td>084850.KQ</td>
<td>ITM Semiconductor Co Ltd</td>
<td>095190.KQ</td>
<td>EMKorea Co Ltd</td>
</tr>
<tr>
<td>085660.KQ</td>
<td>Chabiotech Co Ltd</td>
<td>215360.KQ</td>
<td>Woory Industrial Co Ltd</td>
</tr>
<tr>
<td>214370.KQ</td>
<td>Caregen Co Ltd</td>
<td>215600.KQ</td>
<td>SillaJen Inc</td>
</tr>
<tr>
<td>268600.KQ</td>
<td>Cellivery Therapeutics Inc</td>
<td>217730.KQ</td>
<td>Kang Stem Biotech Co Ltd</td>
</tr>
<tr>
<td>282880.KQ</td>
<td>CowinTech Co Ltd</td>
<td>222040.KQ</td>
<td>Cosmax NBT Inc</td>
</tr>
</tbody>
</table>There is significant volume to buy and sell on quite a few inclusions and exclusions and stocks will move since there are only 11 trading days to implementation.

The KRX announced the list of inclusions and exclusions to the KOSDAQ150 Index today. The rebalance is effective as of 12 June and all passive buying/selling will be done at the closing auction on 11 June.There are 14 inclusions and 14 exclusions in the June 2020 review with an expected one-way turnover of 5.15%.The inclusions and exclusions are shown in the table below








INCLUSIONS
EXCLUSIONS


018290.KQ
VT GMP Co Ltd
007820.KQ
SM Core Inc


032190.KQ
Daou Data Corp
013030.KQ
HY-Lok Corp


038540.KQ
Sangsangin Co Ltd
016250.KQ
eTEC E&amp;C Ltd


041190.KQ
Woori Technology Investment Co Ltd
019210.KQ
YG-1 Co Ltd


052260.KQ
SK Bio Land Co Ltd
036630.KQ
Sejong Telecom Inc


060720.KQ
KH Vatec Co Ltd
041140.KQ
Nexon GT Co Ltd


078020.KQ
eBEST Investment &amp; Securities Co Ltd
044490.KQ
Taewoong Co Ltd


078070.KQ
Ubiquoss Holdings Inc
045100.KQ
Hanyang ENG Co Ltd


084370.KQ
Eugene Technology Co Ltd
067390.KQ
AeroSpace Technology of Korea Inc


084850.KQ
ITM Semiconductor Co Ltd
095190.KQ
EMKorea Co Ltd


085660.KQ
Chabiotech Co Ltd
215360.KQ
Woory Industrial Co Ltd


214370.KQ
Caregen Co Ltd
215600.KQ
SillaJen Inc


268600.KQ
Cellivery Therapeutics Inc
217730.KQ
Kang Stem Biotech Co Ltd


282880.KQ
CowinTech Co Ltd
222040.KQ
Cosmax NBT Inc


There is significant volume to buy and sell on quite a few inclusions and exclusions and stocks will move since there are only 11 trading days to implementation.

KOSDAQ150 Index Review - Let's Not Follow The Index Methodology

Korea / Special Situations, Clepsydra Capital

Sanghyun Park

Korea / Special Situations

Equity Capital Markets

Samsung Electronics / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/16883" target="_blank" data-smartkarma-citation="entities:16883:1">Soulbrain Co Ltd (036830 KS)</a> and <a href="https://www.smartkarma.com/entities/19607" target="_blank" data-smartkarma-citation="entities:19607:1">Dongjin Semichem Co Ltd (005290 KS)</a> decided to do a capital increase through new rights offering. Soulbrain's rights offering will amount to ₩55.6bil, whereas Dongjin Semichem's rights offering will amount to ₩25.1bil. What is important is that these two rights offering will be private placements to a third party. Who is this third party? It is <a href="https://www.smartkarma.com/entities/191" target="_blank" data-smartkarma-citation="entities:191:1">Samsung Electronics Co Ltd (005930 KS)</a>. That is, SamE will spend ₩55.6bil and ₩25.1bil on Soulbrain and Dongjin Semichem for a 4.80% stake and a 2.50% stake, respectively.<div class="content-highlight">Soulbrain's regulatory filing<a href="https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20171030000495" target="_blank">https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20171030000495</a>Dongjin Semichem's regulatory filing<a href="https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20171030000493" target="_blank">https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20171030000493</a></div>Below is a summary of these rights offerings.<table class="table table-striped"><tbody><tr><td>Item</td><td><a href="https://www.smartkarma.com/entities/16883" target="_blank" data-smartkarma-citation="entities:16883:1">Soulbrain Co Ltd (036830 KS)</a></td><td><a href="https://www.smartkarma.com/entities/19607" target="_blank" data-smartkarma-citation="entities:19607:1">Dongjin Semichem Co Ltd (005290 KS)</a></td></tr><tr><td>Offering size</td><td>835,110 common shares</td><td>1,285,360 common shares</td></tr><tr><td>Offering amount</td><td>₩55,618,326,000</td><td>₩25,128,788,000</td></tr><tr><td>Current number of issued shares</td><td>16,563,161 common shares</td><td>50,129,134 common shares</td></tr><tr><td>Capital increase rate</td><td>5.04%</td><td>2.56%</td></tr><tr><td>Shares dilution</td><td>4.80%</td><td>2.50%</td></tr><tr><td>Offering type</td><td>Private placement to the third party</td><td>Private placement to the third party</td></tr><tr><td>Offering price</td><td>₩66,600</td><td>₩19,550</td></tr><tr><td>Listing date of new shares</td><td>Nov 15</td><td>Nov 17</td></tr><tr><td>Lockup period of new shares</td><td>1 year</td><td>1 year</td></tr><tr><td>Use of proceeds</td><td>Production capacity expansion</td><td>Production capacity expansion</td></tr><tr><td colspan="3">Source: DART</td></tr></tbody></table>SamE gets to buy a 4.80% stake of Soulbrain at a 2.49% discount to the Oct 30 closing price of ₩68,300. As for Dongjin Semichem, SamE gets to buy a 2.50% stake at a 7.35% discount to the Oct 30 closing price of ₩21,100.<table class="table table-striped"><tbody><tr><td>Item</td><td><a href="https://www.smartkarma.com/entities/16883" target="_blank" data-smartkarma-citation="entities:16883:1">Soulbrain Co Ltd (036830 KS)</a></td><td><a href="https://www.smartkarma.com/entities/19607" target="_blank" data-smartkarma-citation="entities:19607:1">Dongjin Semichem Co Ltd (005290 KS)</a></td></tr><tr><td>SamE's stake</td><td>4.80%</td><td>2.50%</td></tr><tr><td>Offering price</td><td>₩66,600</td><td>₩19,550</td></tr><tr><td>Closing price on Oct 30</td><td>₩68,300</td><td>₩21,100</td></tr><tr><td> - Discount to Oct 30 closing price</td><td>-2.49%</td><td>-7.35%</td></tr><tr><td colspan="3">Source: DART</td></tr></tbody></table>

Soulbrain Co Ltd (036830 KS) and Dongjin Semichem Co Ltd (005290 KS) decided to do a capital increase through new rights offering. Soulbrain's rights offering will amount to ₩55.6bil, whereas Dongjin Semichem's rights offering will amount to ₩25.1bil. What is important is that these two rights offering will be private placements to a third party. Who is this third party? It is Samsung Electronics Co Ltd (005930 KS). That is, SamE will spend ₩55.6bil and ₩25.1bil on Soulbrain and Dongjin Semichem for a 4.80% stake and a 2.50% stake, respectively.Soulbrain's regulatory filinghttps://dart.fss.or.kr/dsaf001/main.do?rcpNo=20171030000495Dongjin Semichem's regulatory filinghttps://dart.fss.or.kr/dsaf001/main.do?rcpNo=20171030000493Below is a summary of these rights offerings.ItemSoulbrain Co Ltd (036830 KS)Dongjin Semichem Co Ltd (005290 KS)Offering size835,110 common shares1,285,360 common sharesOffering amount₩55,618,326,000₩25,128,788,000Current number of issued shares16,563,161 common shares50,129,134 common sharesCapital increase rate5.04%2.56%Shares dilution4.80%2.50%Offering typePrivate placement to the third partyPrivate placement to the third partyOffering price₩66,600₩19,550Listing date of new sharesNov 15Nov 17Lockup period of new shares1 year1 yearUse of proceedsProduction capacity expansionProduction capacity expansionSource: DARTSamE gets to buy a 4.80% stake of Soulbrain at a 2.49% discount to the Oct 30 closing price of ₩68,300. As for Dongjin Semichem, SamE gets to buy a 2.50% stake at a 7.35% discount to the Oct 30 closing price of ₩21,100.ItemSoulbrain Co Ltd (036830 KS)Dongjin Semichem Co Ltd (005290 KS)SamE's stake4.80%2.50%Offering price₩66,600₩19,550Closing price on Oct 30₩68,300₩21,100 - Discount to Oct 30 closing price-2.49%-7.35%Source: DART

Soulbrain & Dongjin Semichem Rights Offerings - Private Placement to Samsung Electronics

Kolon TissueGene  / Equity Capital Markets

Can you believe this?<a href="https://www.smartkarma.com/entities/25907" target="_blank" data-smartkarma-citation="entities:25907:1">TissueGene Inc. (950160 KS)</a> IPO price was set at ₩27,000. This is the upper end of the indicative price band, ₩16,000 - ₩27,000. The subscription competition rate is 299.49 to 1. A total of 655 local and overseas institutional investors have participated in this bookbuilding process. Foreign investment institutions accounted for 24.12% in terms of participating institutions and 25.52% in terms of demand qty.There is no doubt that this is way better than initially and widely…

Can you believe this?TissueGene Inc. (950160 KS) IPO price was set at ₩27,000. This is the upper end of the indicative price band, ₩16,000 - ₩27,000. The subscription competition rate is 299.49 to 1. A total of 655 local and overseas institutional investors have participated in this bookbuilding process. Foreign investment institutions accounted for 24.12% in terms of participating institutions and 25.52% in terms of demand qty.There is no doubt that this is way better than initially and widely…

TissueGene IPO Part 4 - Bookbuilding Result Review

It is time to decide on <a href="https://www.smartkarma.com/entities/25907" target="_blank" data-smartkarma-citation="entities:25907:1">TissueGene Inc. (950160 KS)</a> IPO. Its bookbuilding is actually taking place today and tomorrow. I know this is a very difficult IPO stock. Opinions are extremely divided. Well, this is no surprise. This is a company that starts pumping real cash only after 2023. Even, this is only if they get US approval for phase III clinical trial, which is only 50% success rate. Alright, I already talked much about this in my previous two insights. So, if you aren't still familiar with these basic stuffs about TissueGene, I invite you to read the following two insights about this IPO.<a href="https://www.smartkarma.com/insights/tissuegene-ipo-part-1-ipo-prospectus-summary" target="_blank" data-smartkarma-citation="insights:13775">TissueGene IPO Part 1 - IPO Prospectus Summary</a><a href="https://www.smartkarma.com/insights/tissuegene-ipo-part-2-facts-about-cartilage-regeneration-us-clinical-trial" target="_blank" data-smartkarma-citation="insights:14051">TissueGene IPO Part 2 - Facts About Cartilage Regeneration &amp; US Clinical Trial</a><table class="table table-striped"><tbody><tr><td colspan="2" style="width: 270.1005554199219px;"><a href="https://www.smartkarma.com/entities/25907" target="_blank" data-smartkarma-citation="entities:25907:1">TissueGene Inc. (950160 KS)</a> IPO summary</td></tr><tr><td style="width: 270.1005554199219px;">Company name</td><td style="width: 458.8994445800781px;"><a href="https://www.smartkarma.com/entities/25907" target="_blank" data-smartkarma-citation="entities:25907:1">TissueGene Inc. (950160 KS)</a></td></tr><tr><td style="width: 270.1005554199219px;">CEO</td><td style="width: 458.8994445800781px;">Lee Woo-sok and Dr. Lee Bum-sup</td></tr><tr><td style="width: 270.1005554199219px;">HQ address</td><td style="width: 458.8994445800781px;">9605 Medical Center Drive, Suite 200, Rockville, MD 20850, United States</td></tr><tr><td style="width: 270.1005554199219px;">Corporate homepage</td><td style="width: 458.8994445800781px;"><a href="http://www.tissuegene.com/" target="_blank">www.tissuegene.com</a></td></tr><tr><td style="width: 270.1005554199219px;">Industry / specialty</td><td style="width: 458.8994445800781px;">It is a clinical-stage bio-pharmaceutical company focused on developing novel regenerative therapies in the field of cell therapy.</td></tr><tr><td style="width: 270.1005554199219px;">Total number of share offerings</td><td style="width: 458.8994445800781px;">7,500,000 DRs (depositary receipt) since the company is headquartered in the US.(100% new rights offering)</td></tr><tr><td style="width: 270.1005554199219px;">Indicative price band</td><td style="width: 458.8994445800781px;">₩16,000 - ₩27,000</td></tr><tr><td style="width: 270.1005554199219px;">Total amount to be raised (at ₩16,000)</td><td style="width: 458.8994445800781px;">₩120,000,000,000</td></tr><tr><td style="width: 270.1005554199219px;">Target valuation (at ₩16,000)</td><td style="width: 458.8994445800781px;">₩1.01tril (US$894mil)</td></tr><tr><td style="width: 270.1005554199219px;">Lead manager</td><td style="width: 458.8994445800781px;"><a href="https://www.smartkarma.com/entities/18790" target="_blank" data-smartkarma-citation="entities:18790:1">NH Investment &amp; Securities Co Ltd (005940 KS)</a></td></tr><tr><td style="width: 270.1005554199219px;">Co managers</td><td style="width: 458.8994445800781px;">KISHana Financial &amp; Investment Securities<a href="https://www.smartkarma.com/entities/10558" target="_blank" data-smartkarma-citation="entities:10558:1">Hanwha Securities Co Ltd (003530 KS)</a><a href="https://www.smartkarma.com/entities/18895" target="_blank" data-smartkarma-citation="entities:18895:1">Ebest Investment &amp; Securitie (078020 KS)</a></td></tr><tr><td style="width: 270.1005554199219px;">Bourse</td><td style="width: 458.8994445800781px;">KOSDAQ</td></tr><tr><td colspan="2" style="width: 729px;">Source: DART</td></tr></tbody></table>

It is time to decide on TissueGene Inc. (950160 KS) IPO. Its bookbuilding is actually taking place today and tomorrow. I know this is a very difficult IPO stock. Opinions are extremely divided. Well, this is no surprise. This is a company that starts pumping real cash only after 2023. Even, this is only if they get US approval for phase III clinical trial, which is only 50% success rate. Alright, I already talked much about this in my previous two insights. So, if you aren't still familiar with these basic stuffs about TissueGene, I invite you to read the following two insights about this IPO.TissueGene IPO Part 1 - IPO Prospectus SummaryTissueGene IPO Part 2 - Facts About Cartilage Regeneration &amp; US Clinical TrialTissueGene Inc. (950160 KS) IPO summaryCompany nameTissueGene Inc. (950160 KS)CEOLee Woo-sok and Dr. Lee Bum-supHQ address9605 Medical Center Drive, Suite 200, Rockville, MD 20850, United StatesCorporate homepagewww.tissuegene.comIndustry / specialtyIt is a clinical-stage bio-pharmaceutical company focused on developing novel regenerative therapies in the field of cell therapy.Total number of share offerings7,500,000 DRs (depositary receipt) since the company is headquartered in the US.(100% new rights offering)Indicative price band₩16,000 - ₩27,000Total amount to be raised (at ₩16,000)₩120,000,000,000Target valuation (at ₩16,000)₩1.01tril (US$894mil)Lead managerNH Investment &amp; Securities Co Ltd (005940 KS)Co managersKISHana Financial &amp; Investment SecuritiesHanwha Securities Co Ltd (003530 KS)Ebest Investment &amp; Securitie (078020 KS)BourseKOSDAQSource: DART

TissueGene IPO Part 3 - More Fact Gathering from Yesterday's Press Meeting

South Korea

LS SECURITIES Co. Ltd. operates financial related businesses. The Company provides securities intermediaries, investment consulting, and other services. LS SECURITIES conducts businesses in South Korea.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

LS SECURITIES Co Ltd (078020 KS)

KOSDAQ150 Index Rebalance Preview: Lots of Changes Expected Already; More to Come

Less than a third of the way through the review period, we see 14 potential inclusions and exclusions from the KOSDAQ150 index. The resumption of...

Brian Freitas

KOSDAQ150 Index Review - Let's Not Follow The Index Methodology

The KRX announced the list of inclusions and exclusions to the KOSDAQ150 Index today. The rebalance is effective as of 12 June and all passive...

Brian Freitas

Soulbrain & Dongjin Semichem Rights Offerings - Private Placement to Samsung Electronics

Soulbrain Co Ltd (036830 KS) and Dongjin Semichem Co Ltd (005290 KS) decided to do a capital increase through new rights offering. Soulbrain's...

Sanghyun Park

TissueGene IPO Part 4 - Bookbuilding Result Review

Can you believe this?TissueGene Inc. (950160 KS) IPO price was set at ₩27,000. This is the upper end of the indicative price band, ₩16,000 -...

Sanghyun Park

TissueGene IPO Part 3 - More Fact Gathering from Yesterday's Press Meeting

It is time to decide on TissueGene Inc. (950160 KS) IPO. Its bookbuilding is actually taking place today and tomorrow. I know this is a very...

Sanghyun Park

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)